Pancreatic polypeptide family (APP, BPP, NPY and PYY) in relation to sympathetic vasoconstriction resistant to alpha-adrenoceptor blockade.
D000319:Adrenergic beta-Antagonists / Q000494:pharmacology*; D000818:Animals; D002415:Cats; D004558:Electric Stimulation; D005260:Female; D006439:Hemodynamics / Q000187:drug effects; D008297:Male; D009419:Nerve Tissue Proteins / Q000494:pharmacology; D009478:Neuropeptide Y; D009541:Nictitating Membrane / Q000187:drug effects; D009638:Norepinephrine / Q000494:pharmacology; D010191:Pancreatic Polypeptide / Q000494:pharmacology*; D019894:Peptide YY; D010455:Peptides / Q000494:pharmacology; D010646:Phentolamine / Q000494:pharmacology; D011433:Propranolol / Q000494:pharmacology; D012463:Saliva / Q000378:metabolism; D013363:Submandibular Gland / Q000098:blood supply*; D013564:Sympathetic Nervous System / Q000502:physiology; D014661:Vasoconstriction / Q000187:drug effects*
D000319:Adrenergic beta-Antagonists; D009419:Nerve Tissue Proteins; D009478:Neuropeptide Y; D010455:Peptides; D019894:Peptide YY; D010191:Pancreatic Polypeptide; D011433:Propranolol; D009638:Norepinephrine; D010646:Phentolamine